Today, Kamada Ltd. (TASE: KMDA) reported interim results of the Phase III trial for its aerosolized AAT for the treatment of congenital emphysema. The trial was carried out with the European Medicines Agency (EMA).
According to the company, the trial showed very good safety results for the product even after 13 months. No information has yet been released about the efficacy of the product. This will be included only with the final results.
Congenital emphysema is currently treated by infusion of AAT, and Kamada will be the first company to offer direct delivery of AAT to the lungs by inhalation.
Separately, Prolor Biotech received the go ahead from its safety committee today to proceed with its trial. Prolor is conducting a Phase II trial for a longer-acting growth hormone.
Unlike Kamada, Prolor does not have precise safety results, but clearly no substantial safety problems have been encountered so far. According to the company, the trial is proceeding as planned, and should be completed by mid-2011.
Published by Globes [online], Israel business news - www.globes-online.com - on February 14, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011